Related references
Note: Only part of the references are listed.A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
Andrzej J. Jakubowiak et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
Don M. Benson et al.
BLOOD (2011)
Monoclonal antibodies in the treatment of multiple myeloma
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease
Achille Aouba et al.
BLOOD (2010)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells
Don M. Benson et al.
BLOOD (2009)
Monoclonal antibodies for cancer immunotherapy
Louis M. Weiner et al.
LANCET (2009)
Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function
Mario-Ernesto Cruz-Munoz et al.
NATURE IMMUNOLOGY (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay
Vidya Kondadasula et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
Jumei Shi et al.
BLOOD (2008)
NTB-A receptor crystal structure: Insights into homophilic interactions in the signaling lymphocytic activation molecule receptor family
Erhu Cao et al.
IMMUNITY (2006)
Evidence for discrete stages of human natural killer cell differentiation in vivo
AG Freud et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells
S Stark et al.
INTERNATIONAL IMMUNOLOGY (2006)
The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cγ signaling pathways in human NK cells
I Tassi et al.
JOURNAL OF IMMUNOLOGY (2005)
The biology of human natural killer-cell subsets
MA Cooper et al.
TRENDS IN IMMUNOLOGY (2001)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Share Paper
